Merck, Ridgeback Announce New Molnupiravir Data From Late-Stage COVID-19 Study

  • Merck & Co Inc MRK and Ridgeback Biotherapeutics announced that the Annals of Internal Medicine had published additional data from the Phase 3 MOVe-OUT trial of Lagevrio (molnupiravir) in non-hospitalized COVID-19 patients at high risk for progressing to severe disease.
  • A lower proportion of molnupiravir-treated participants in the modified intent-to-treat population had an acute care visit or a COVID-19-related acute care visit versus a placebo.
  • 7.2% of participants who received Lagevrio reported an acute care visit through Day 29, versus 10.6% of placebo participants, with a relative risk reduction of 32.1%.
  • Related: See Why Did FDA Update Merck's COVID-19 Pill Emergency Use Authorization.
  • 6.6% of participants who received Lagevrio reported a COVID-19-related acute care visit, versus 10.0% of placebo participants, with a RRR of 33.8%.
  • Based on a post hoc analysis, fewer Lagevrio-treated participants required respiratory interventions versus placebo-treated participants, with a RRR of 34.3%. 
  • Lagevrio is being evaluated for post-exposure prophylaxis in the MOVe-AHEAD Phase 3 study of Lagevrio in preventing the spread of COVID-19 within households.
  • Price Action: MRK shares are up 0.07% at $89.90 during the market session on the last check Tuesday.

Posted In: BriefsCOVID-19 CoronavirusBiotechLarge CapNewsHealth CareGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.